menu
    • menu

    Company profile for Rapt Therapeutics

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Willow Birch Pharma delivers trusted, high-quality APIs nationwide with unmatched service, compliance, and competitive value.

    Virtual Booth

    Contact Supplier

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    RAPT Therapeutics is a clinical-stage biopharmaceutical company driven by a bold mission—to conquer cancer and inflammatory disease in our lifetime. Our cutting-edge science is fully focused on developing oral therapeutics that intelligently target key drivers of the immune system to transform the treatment of cancer and inflammation, and improve and empower countless lives.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Rapt TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    561 Eccles Avenue South San Francisco, CA 94080
    Telephone
    Telephone
    +1 650 489 9000
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://rapt.com/
    Linkedin
    Linkedin
    https://in.linkedin.com/company/rapt
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    DCAT Week

    DCAT Week

    Not Confirmed

    envelop Contact Supplier

    DCAT Week

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    RAPT Therapeutics Unveils Q3 2025 Financials & Highlights
    RAPT Therapeutics Unveils Q3 2025 Financials & Highlights

    06 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/06/3182495/0/en/RAPT-Therapeutics-Reports-Third-Quarter-2025-Financial-Results-and-Recent-Highlights.html

    GLOBENEWSWIRE
    06 Nov 2025
    Share Share
    RAPT Pharma Joins Investor Conferences
    RAPT Pharma Joins Investor Conferences

    04 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/04/3180863/0/en/RAPT-Therapeutics-to-Participate-in-Multiple-Upcoming-Investor-Conferences.html

    GLOBENEWSWIRE
    04 Nov 2025
    Share Share
    RAPT Therapeutics Launches Prestige Ph 2B Trial Of Ozureprubart
    RAPT Therapeutics Launches Prestige Ph 2B Trial Of Ozureprubart

    27 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/27/3174511/0/en/RAPT-Therapeutics-Initiates-prestIgE-Phase-2b-Clinical-Trial-of-Ozureprubart-RPT904-in-Patients-with-Food-Allergies.html

    GLOBENEWSWIRE
    27 Oct 2025
    Share Share
    RAPT Therapeutics Plans Public Stock Offering
    RAPT Therapeutics Plans Public Stock Offering

    21 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/21/3170617/0/en/RAPT-Therapeutics-Announces-Proposed-Public-Offering-of-Common-Stock.html

    GLOBENEWSWIRE
    21 Oct 2025
    Share Share
    RAPT Pharma And Shanghai Jeyou Pharma Report Phase 2 Success
    RAPT Pharma And Shanghai Jeyou Pharma Report Phase 2 Success

    20 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/20/3169321/0/en/RAPT-Therapeutics-and-Shanghai-Jeyou-Pharmaceutical-Announce-Positive-Topline-Data-from-Phase-2-Trial-of-RPT904-JYB1904-in-Chronic-Spontaneous-Urticaria.html

    GLOBENEWSWIRE
    20 Oct 2025
    Share Share
    RPT Therapeutics To Release Phase 2 Results For RPT904
    RPT Therapeutics To Release Phase 2 Results For RPT904

    19 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/19/3169017/0/en/RAPT-Therapeutics-to-Report-Topline-Data-from-Phase-2-Clinical-Trial-of-RPT904-in-Chronic-Spontaneous-Urticaria-CSU.html

    GLOBENEWSWIRE
    19 Oct 2025
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search